Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
GKGlaukos Corporation logo

Glaukos Corporation (GKOS)

New York Stock Exchange · Currency in USD
$178.88 ▲ +2.19 (+1.24%)
At close: Oct 23, 4:00 PM ET. Market closed.
$178.88 ▲ +0.00 (+0.00%)
After hours: Oct 23, 5:22 PM ET

Summary

Previous Close
$176.69
Open
$175.95
Day's Range
$173.08 – $179.70
52 Week Range
$73.16 – $191.62
Volume
961,023
Avg. Volume
856,042
Market Cap
$10.55B
Beta (5Y Monthly)
0.70
PE Ratio (TTM)
--
EPS (TTM)
-$3.22
Earnings Date
Oct 28, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$192.90

Profile: Glaukos Corporation

Sector
Healthcare
Industry
Medical - Devices
Full-time employees
1,094
CEO
Thomas William Burns

Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma.

Earnings

Next report: Wed, Oct 28, 2026
EPS estimate -$0.10 · Revenue est. $168.04M
DateEst.Actual
Jul 29, 2026-$0.21-$0.14Beat
Apr 29, 2026-$0.30-$0.18Beat
Feb 17, 2026-$0.22-$0.28Miss
Oct 29, 2025-$0.27-$0.16Beat
Jul 30, 2025-$0.26-$0.24Beat
Apr 30, 2025-$0.33-$0.22Beat

Analyst view

Consensus price target
$192.90 ▲ +7.8%
Range $150.00 – $215.00
Rating: Buy
Buy 72% · Hold 24% · Sell 4%

Get free alerts on GKOS and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.